Please assess the completion status of the following clinical trial:

Trial Title: Infliximab Accelerated Induction in Moderate to Severe Pediatric UC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ulcerative colitis~2. PUCAI≥35~3. Age: 6 - 17 years (inclusive)~4. Planned to initiate IFX therapy.~5. Naïve to biologics~6. Informed consent~7. Neg. PPD-Test, negative HBV- S Ag~8. Negative stool culture, parasites and clostridium toxin~Exclusion Criteria:~1. Pregnancy.~2. Acute severe colitis.~3. Renal Failure.~4. Toxic megacolon.~5. Patients whose disease is confined to the rectum (i.e. proctitis).~6. Prior treatment with infliximab or adalimumab.~7. Previous malignancy.~8. Sepsis or active bacterial infection.~9. Known immune deficiency.~10. Positive Hepatitis B surface antigen or evidence for TB.~11. IBD unclassified.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Accelerated induction (Type: EXPERIMENTAL): Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
- Per protocol (Type: ACTIVE_COMPARATOR): Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).